Tags

Type your tag names separated by a space and hit enter

The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
J Invasive Cardiol. 2004 Feb; 16(2):46-51.JI

Abstract

OBJECTIVES

This study was designed to assess the feasibility and safety of enoxaparin in combination with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) as part of an early invasive strategy in patients presenting with acute coronary syndromes (ACS).

BACKGROUND

Trials in patients with ACS have evaluated the utility of enoxaparin, adjuvant GP IIb/IIIa inhibitors with PCI, and an early invasive approach. Information about the combination of all three of these approaches, however, is limited.

METHODS

Forty-nine patients with ACS underwent cardiac catheterization, of whom 23 underwent PCI with enoxaparin and GP IIb/IIIa inhibitors.

RESULTS

The primary endpoint of the study, a composite of death, myocardial infarction or urgent revascularization at 30 days, occurred in 8% of patients undergoing PCI. There were no deaths. One patient received a blood transfusion. No other adverse events occurred. These event rates were comparable to those from the pooled EPILOG/EPISTENT database, in which intravenous unfractionated heparin was used in conjunction with GP IIb/IIIa receptor blockade. The mean anti-Xa level in patients undergoing PCI was 0.74 0.48 U/ml. The majority of patients who underwent PCI within eight hours of their last dose of enoxaparin had therapeutic anti-Xa levels.

CONCLUSION

In patients with ACS, enoxaparin in combination with GP IIb/IIIa inhibitors and an early invasive approach resulted in comparable clinical complication and bleeding rates versus historical references utilizing unfractionated heparin.

Authors+Show Affiliations

Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. bhattd@ccf.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14760188

Citation

Lee, David S., et al. "The Combination of Enoxaparin, Glycoprotein IIb/IIIa Inhibitors and an Early Invasive Approach Among Acute Coronary Syndrome Patients." The Journal of Invasive Cardiology, vol. 16, no. 2, 2004, pp. 46-51.
Lee DS, Bhatt DL, Moliterno DJ, et al. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol. 2004;16(2):46-51.
Lee, D. S., Bhatt, D. L., Moliterno, D. J., Peacock, W. F., Ellis, S. G., & Topol, E. J. (2004). The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. The Journal of Invasive Cardiology, 16(2), 46-51.
Lee DS, et al. The Combination of Enoxaparin, Glycoprotein IIb/IIIa Inhibitors and an Early Invasive Approach Among Acute Coronary Syndrome Patients. J Invasive Cardiol. 2004;16(2):46-51. PubMed PMID: 14760188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. AU - Lee,David S, AU - Bhatt,Deepak L, AU - Moliterno,David J, AU - Peacock,W Frank, AU - Ellis,Stephen G, AU - Topol,Eric J, PY - 2004/2/5/pubmed PY - 2005/2/11/medline PY - 2004/2/5/entrez SP - 46 EP - 51 JF - The Journal of invasive cardiology JO - J Invasive Cardiol VL - 16 IS - 2 N2 - OBJECTIVES: This study was designed to assess the feasibility and safety of enoxaparin in combination with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) as part of an early invasive strategy in patients presenting with acute coronary syndromes (ACS). BACKGROUND: Trials in patients with ACS have evaluated the utility of enoxaparin, adjuvant GP IIb/IIIa inhibitors with PCI, and an early invasive approach. Information about the combination of all three of these approaches, however, is limited. METHODS: Forty-nine patients with ACS underwent cardiac catheterization, of whom 23 underwent PCI with enoxaparin and GP IIb/IIIa inhibitors. RESULTS: The primary endpoint of the study, a composite of death, myocardial infarction or urgent revascularization at 30 days, occurred in 8% of patients undergoing PCI. There were no deaths. One patient received a blood transfusion. No other adverse events occurred. These event rates were comparable to those from the pooled EPILOG/EPISTENT database, in which intravenous unfractionated heparin was used in conjunction with GP IIb/IIIa receptor blockade. The mean anti-Xa level in patients undergoing PCI was 0.74 0.48 U/ml. The majority of patients who underwent PCI within eight hours of their last dose of enoxaparin had therapeutic anti-Xa levels. CONCLUSION: In patients with ACS, enoxaparin in combination with GP IIb/IIIa inhibitors and an early invasive approach resulted in comparable clinical complication and bleeding rates versus historical references utilizing unfractionated heparin. SN - 1042-3931 UR - https://www.unboundmedicine.com/medline/citation/14760188/The_combination_of_enoxaparin_glycoprotein_IIb/IIIa_inhibitors_and_an_early_invasive_approach_among_acute_coronary_syndrome_patients_ L2 - https://medlineplus.gov/bloodthinners.html DB - PRIME DP - Unbound Medicine ER -